<i>
              <scp>KIT</scp>
            </i>
            mutations and
            <scp>CD</scp>
            117 overexpression are markers of better progression‐free survival in vulvar melanomas

Dias‐Santagata, Dora; Selim, M. Angélica; Su, Yongxuan; Peng, Yan; Vollmer, Robin T.; Chlopik, Agata; Tell‐Martí, Gemma; Paral, Kristen M.; Shalin, Sara C.; Shea, Christopher R.; Puig, Susana; Fernández‐Figueras, María Teresa; Biernat, Wojciech; Ryś, Janusz; Marszałek, Andrzej; Hoang, Mai P.

doi:10.1111/bjd.15836

Cited by 20 publications

(14 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detected mutations were in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%), and telomerase reverse transcriptase promotor (9%). In a univariate analysis, KIT mutations were notably related to a better PFS (hazard ratio: 0.29, p = 0.0013) [ 51 ]. Compared with vulvovaginal melanomas with KIT mutations, vulvovaginal melanomas with wild-type KIT mutations tended to express molecular markers suggestive of platinum resistance (ERCC1), alkylating sensitivity (MGMT), and anthracycline sensitivity (TOP2A) [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Current Status and Prospects of Immunotherapy for Gynecologic Melanoma

Anko

Kobayashi

Banno

et al. 2021

JPM

View full text Add to dashboard Cite

Gynecologic melanomas are rare and have a poor prognosis. Although immunotherapy (immune checkpoint inhibitors) and targeted therapy has greatly improved the systemic treatment of cutaneous melanoma (CM) in recent years, its efficacy in gynecologic melanomas remains uncertain because of the rarity of this malignancy and its scarce literature. This review aimed to evaluate the literature of gynecologic melanomas treated with immunotherapy and targeted therapy through a PubMed search. We identified one study focusing on the overall survival of gynecologic melanomas separately and five case series and nine case reports concentrating on gynecologic melanomas treated with an immune checkpoint inhibitor and/or targeted therapy. Furthermore, the KIT mutation has the highest rate among all mutations in mucosal melanoma types. The KIT inhibitors (Tyrosine kinase inhibitors: TKIs) imatinib and nilotinib could be the treatment options. Moreover, immune checkpoint inhibitors combined with KIT inhibitors may potentially treat cases of resistance to immune checkpoint inhibitors. However, because of the different conditions and a small number of cases, it is difficult to evaluate the efficacy of immunotherapy and targeted therapy for gynecologic melanoma rigorously at this time. Further prospective cohort or randomized trials of gynecologic melanoma alone are needed to assess the treatment with solid evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Current Status and Prospects of Immunotherapy for Gynecologic Melanoma

Anko

Kobayashi

Banno

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Melanomas on the vulvar hair bearing skin are excluded. NRAS, KIT and BRAF mutational results of 72 sinonasal, 27 vulvar and 4 vaginal melanomas; and SF3B1 results of 72 sinonasal melanomas from prior studies were included [11][12][13].…”

Section: Methodsmentioning

confidence: 99%

“…In a series of 444 mucosal melanomas from a European population investigated by Sanger sequencing, NRAS , KIT and BRAF mutations were evenly distributed across the different mucosal melanoma subgroups [ 8 ]. The prognostic role of these commonly recurrent mutations in mucosal melanomas has only been studied in some series [ 6 , 7 , 11 , 12 ]. In a large series of 706 mucosal melanomas, KIT and BRAF mutational status did not correlate with overall survival (OS); however, NRAS was not analyzed in this series [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas

Wróblewska

Dias‐Santagata

Ustaszewski

et al. 2021

Cells

View full text Add to dashboard Cite

Background: The prognostic value of commonly recurrent mutations remains unclear in mucosal melanomas. Methods: Clinicopathologic parameters of 214 cases of mucosal melanomas diagnosed in 1989–2020 in several clinical institutions were analyzed. NRAS, KIT, BRAF, IGF2R and SF3B1 mutational analyses by Sanger sequencing and next generation sequencing-based assay were performed in a subset of cases. Results: Of the triple (BRAF, NRAS, NF1)-negative cases, APC, KIT and KRAS are detected mainly in sinonasal, vulvovaginal and anorectal melanomas, respectively. NRAS, KIT, BRAF, IGF2R and SF3B1 mutations are detected in 19% (37/198), 22% (44/197), 12% (25/201), 16% (22/138) and 15% (20/133) of cases, respectively. In univariate analyses, advanced stage (p = 0.016), 65 years or older (p = 0.048) and presence of ulceration (p = 0.027) are significantly correlated with worse overall survival (OS), respectively. NRAS mutation significantly correlates with worse OS (p = 0.028) and worse melanoma-specific survival (MSS) (p = 0.03) for all cases of mucosal melanomas. In multivariate analyses, NRAS mutation remains as an independent predictor of worse OS (p = 0.036) and worse MSS (p = 0.024). Conclusion: NRAS mutation is a predictor of worse survival, independent of stage in mucosal melanomas. The significance of frequently mutated IGF2R in mucosal melanomas remains unclear.

show abstract

“…In the article by Dias‐Santagata et al , an author's surname in the fourth reference was misspelt as Nagarian P. It should have been Nagarajan P.…”

mentioning

confidence: 99%

Corrigenda

2018

Br J Dermatol

View full text Add to dashboard Cite

KIT mutations and CD 117 overexpression are markers of better progression‐free survival in vulvar melanomas

Abstract: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.

Cited by 20 publications

References 51 publications

Current Status and Prospects of Immunotherapy for Gynecologic Melanoma

Current Status and Prospects of Immunotherapy for Gynecologic Melanoma

Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas

Corrigenda

Contact Info

Product

Resources

About